Related Experiment Video
Updated: Sep 14, 2025

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
Published on: July 25, 2025
Spatial transcriptomics reveals macrophage domestication by epithelial cells promotes immunotherapy resistance in
Yu Sun1, Minghui Zhang1, Yanbin Zhao1
1Harbin Medical University Cancer Hospital, Harbin, China.
Abstract:
Small cell lung cancer (SCLC) remains a lethal malignancy. Although immunochemotherapy regimens have improved patient survival rates, drug resistance still occurs in a significant subset of patients, highlighting the importance of elucidating the mechanisms within the tumor microenvironment. Here, we applied spatial single-cell transcriptomics to investigate the spatial characteristics of SCLC and their associations with immunochemotherapy resistance. By analyzing samples from 18 patients with extensive-stage SCLC, we identified two distinct epithelial cell subtypes: Epi-I and Epi-II. Epi-I exhibited high proliferative activity and was associated with treatment resistance and poor survival outcomes. In contrast, Epi-II showed more spatial contact with immune cells and was associated with treatment sensitivity. Further analysis uncovered a fascinating cellular transition paradigm, wherein Epi-I may be derived from Epi-II, with myeloid cells playing a facilitatory role in this transformation cascade. Specifically, within the spatial zone that was enriched with the Epi-II, epithelial cells may secrete MIF gene, which promoted the polarization of myeloid cells towards the M2 macrophages. The M2-polarized myeloid cells subsequently upregulated the expression of SPP1 that in turn triggered the activation of the PI3K-AKT signaling pathway in the adjacent epithelial cells, driving the conversion of Epi-II to Epi-I cells. Our findings revealed that the intricate crosstalk between epithelial and myeloid cells constitutes a pivotal resistance mechanism in SCLC, and targeting the SPP1/MIF pathway emerged as a promising strategy with the potential to enhance the treatment efficacy.
Insights
Small cell lung cancer (SCLC) drug resistance is linked to tumor microenvironment interactions. Targeting the SPP1/MIF pathway may overcome resistance by preventing epithelial cell transformation.
Area of Science:
- Oncology
- Cancer Biology
- Immunology
Background:
- Small cell lung cancer (SCLC) is a deadly malignancy with frequent treatment resistance.
- Understanding tumor microenvironment mechanisms is crucial for improving SCLC therapy outcomes.
Purpose of the Study:
- To investigate spatial transcriptomic characteristics of SCLC and their association with immunochemotherapy resistance.
- To elucidate the cellular crosstalk driving treatment resistance in SCLC.
Main Methods:
- Spatial single-cell transcriptomics applied to 18 extensive-stage SCLC patient samples.
- Identification and characterization of distinct epithelial cell subtypes (Epi-I and Epi-II).
- Analysis of intercellular communication pathways involving epithelial and myeloid cells.
Main Results:
- Two epithelial subtypes identified: proliferative Epi-I (resistant) and immune-contacting Epi-II (sensitive).
- Epi-I cells appear to arise from Epi-II cells, facilitated by myeloid cells.
- MIF secretion by Epi-II promotes M2 macrophage polarization, upregulating SPP1, activating PI3K-AKT in epithelial cells, driving Epi-II to Epi-I conversion.
Conclusions:
- Epithelial-myeloid cell crosstalk is a key SCLC resistance mechanism.
- The SPP1/MIF pathway is implicated in the epithelial cell transition driving resistance.
- Targeting the SPP1/MIF pathway presents a potential strategy to enhance SCLC treatment efficacy.

